| Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. | Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial.
Gkarmiris KI, Lindbäck J, Alexander JH, Granger CB, Kastner P, Lopes RD, Ziegler A, Oldgren J, Siegbahn A, Wallentin L, Hijazi Z., Free PMC Article | 04/12/2024 |
| Bone Morphogenetic Protein 10-A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation. | Bone Morphogenetic Protein 10-A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation.
Hennings E, Blum S, Aeschbacher S, Coslovsky M, Knecht S, Eken C, Lischer M, Paladini RE, Krisai P, Reichlin T, Rodondi N, Beer JH, Ammann P, Conte G, De Perna ML, Kobza R, Blum MR, Bossard M, Kastner P, Ziegler A, Müller C, Bonati LH, Pfister O, Zuern CS, Conen D, Kühne M, Osswald S, Swiss‐AF Investigators., Free PMC Article | 03/26/2023 |
| Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. | Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation.
Hijazi Z, Benz AP, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Granger CB, Kastner P, Lopes RD, Ziegler A, Oldgren J, Siegbahn A, Wallentin L., Free PMC Article | 03/10/2023 |
| Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10. | Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10.
Guo J, Liu B, Thorikay M, Yu M, Li X, Tong Z, Salmon RM, Read RJ, Ten Dijke P, Morrell NW, Li W., Free PMC Article | 05/21/2022 |
| BMP9 and BMP10: Two close vascular quiescence partners that stand out. | BMP9 and BMP10: Two close vascular quiescence partners that stand out.
Desroches-Castan A, Tillet E, Bouvard C, Bailly S. | 04/16/2022 |
| Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an ""HHT-like"" syndrome in children. | Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children.
Hodgson J, Ruiz-Llorente L, McDonald J, Quarrell O, Ugonna K, Bentham J, Mason R, Martin J, Moore D, Bergstrom K, Bayrak-Toydemir P, Wooderchak-Donahue W, Morrell NW, Condliffe R, Bernabeu C, Upton PD., Free PMC Article | 03/26/2022 |
| BMP9 and BMP10 Act Directly on Vascular Smooth Muscle Cells for Generation and Maintenance of the Contractile State. | BMP9 and BMP10 Act Directly on Vascular Smooth Muscle Cells for Generation and Maintenance of the Contractile State.
Wang L, Rice M, Swist S, Kubin T, Wu F, Wang S, Kraut S, Weissmann N, Böttger T, Wheeler M, Schneider A, Braun T. | 01/1/2022 |
| Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10. | Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Owen NE, Nyimanu D, Kuc RE, Upton PD, Morrell NW, Alexander GJ, Maguire JJ, Davenport AP., Free PMC Article | 12/4/2021 |
| Endothelial protective factors BMP9 and BMP10 inhibit CCL2 release by human vascular endothelial cells. | Endothelial protective factors BMP9 and BMP10 inhibit CCL2 release by human vascular endothelial cells.
Upton PD, Park JES, De Souza PM, Davies RJ, Griffiths MJD, Wort SJ, Morrell NW., Free PMC Article | 06/26/2021 |
| Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. | Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation.
Reyat JS, Chua W, Cardoso VR, Witten A, Kastner PM, Kabir SN, Sinner MF, Wesselink R, Holmes AP, Pavlovic D, Stoll M, Kääb S, Gkoutos GV, de Groot JR, Kirchhof P, Fabritz L., Free PMC Article | 06/12/2021 |
| Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis. | Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis.
Owen NE, Alexander GJ, Sen S, Bunclark K, Polwarth G, Pepke-Zaba J, Davenport AP, Morrell NW, Upton PD., Free PMC Article | 04/17/2021 |
| In Search of ""Hepatic Factor"": Lack of Evidence for ALK1 Ligands BMP9 and BMP10. | In Search of "Hepatic Factor": Lack of Evidence for ALK1 Ligands BMP9 and BMP10.
Capasso TL, Trucco SM, Hindes M, Schwartze T, Bloch JL, Kreutzer J, Cook SC, Hinck CS, Treggiari D, Feingold B, Hinck AP, Roman BL., Free PMC Article | 02/13/2021 |
| Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. | Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases.
Eyries M, Montani D, Nadaud S, Girerd B, Levy M, Bourdin A, Trésorier R, Chaouat A, Cottin V, Sanfiorenzo C, Prevot G, Reynaud-Gaubert M, Dromer C, Houeijeh A, Nguyen K, Coulet F, Bonnet D, Humbert M, Soubrier F. | 10/10/2020 |
| BMP9/10 in Pulmonary Vascular Complications of Liver Disease. | BMP9/10 in Pulmonary Vascular Complications of Liver Disease.
Rochon ER, Krowka MJ, Bartolome S, Heresi GA, Bull T, Roberts K, Hemnes A, Forde KA, Krok KL, Patel M, Lin G, McNeil M, Al-Naamani N, Roman BL, Yu PB, Fallon MB, Gladwin MT, Kawut SM., Free PMC Article | 09/5/2020 |
| W143*-NRG1and V470I-BMP10 variants are associated with left ventricular non-compaction. | Familial Left Ventricular Non-Compaction Is Associated With a Rare p.V407I Variant in Bone Morphogenetic Protein 10.
Hirono K, Saito K, Munkhsaikhan U, Xu F, Wang C, Lu L, Ichida F, Towbin JA, Purevjav E. | 08/12/2020 |
| BMP10 was able to promote cardiomyocyte survival and prevent cardiac adverse remodeling. Additional experiments with the de novo activation of BMP10 in the postnatal heart and the treatment of recombinant human BMP10 (rhBMP10) further confirmed this observation. A novel activity of BMP10 is in activating both SMAD- and STAT3- mediated signaling pathways. | BMP10 preserves cardiac function through its dual activation of SMAD-mediated and STAT3-mediated pathways.
Qu X, Liu Y, Cao D, Chen J, Liu Z, Ji H, Chen Y, Zhang W, Zhu P, Xiao D, Li X, Shou W, Chen H., Free PMC Article | 06/27/2020 |
| Findings demonstrate that GDF2 mutations result in BMP9 loss of function and are likely causal for pulmonary arterial hypertension. These mutations lead to reduced circulating levels of both BMP9 and BMP10. | Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension.
Hodgson J, Swietlik EM, Salmon RM, Hadinnapola C, Nikolic I, Wharton J, Guo J, Liley J, Haimel M, Bleda M, Southgate L, Machado RD, Martin JM, Treacy CM, Yates K, Daugherty LC, Shamardina O, Whitehorn D, Holden S, Bogaard HJ, Church C, Coghlan G, Condliffe R, Corris PA, Danesino C, Eyries M, Gall H, Ghio S, Ghofrani HA, Gibbs JSR, Girerd B, Houweling AC, Howard L, Humbert M, Kiely DG, Kovacs G, Lawrie A, MacKenzie Ross RV, Moledina S, Montani D, Olschewski A, Olschewski H, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Prokopenko I, Rhodes CJ, Scelsi L, Seeger W, Soubrier F, Suntharalingam J, Toshner MR, Trembath RC, Vonk Noordegraaf A, Wort SJ, Wilkins MR, Yu PB, Li W, Gräf S, Upton PD, Morrell NW., Free PMC Article | 05/23/2020 |
| Low BMP10 expression is associated with hepatocellular carcinoma progression. | BMP10 suppresses hepatocellular carcinoma progression via PTPRS-STAT3 axis.
Yuan YM, Ma N, Zhang EB, Chen TW, Jiang H, Yin FF, Wang JJ, Zhang FK, Ni QZ, Wang X, Bao Y, Wang K, Cheng SQ, Zhang XL, Wang XF, Li JJ, Xie D. | 03/21/2020 |
| Low BMP-10 expression was associated with poor prognosis and progression of ovarian cancer | Loss of BMP-10 is correlated with poor survival in ovarian cancer.
Jin Y, Zheng W, Li L, Huang G, Liu Y, Jiang H, Zhang Y, Tang C. | 02/9/2019 |
| Data suggest BMP9/GDF2 and BMP10 synergize with TNFA to increase monocyte recruitment to vascular endothelial cells; process appears to be mediated mainly via ALK2/ACVR1 (which exhibits protein kinase activity). These studies used in vitro flow monocyte adhesion assay. (BMP9 = growth differentiation factor 2; BMP10 = bone morphogenetic protein 10; TNFA = tumor necrosis factor alpha; ALK2/ACVR1 = activin A receptor type 1) | Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.
Mitrofan CG, Appleby SL, Nash GB, Mallat Z, Chilvers ER, Upton PD, Morrell NW., Free PMC Article | 09/9/2017 |
| Bone morphogenetic protein (BMP)9 and BMP10 are high affinity ligands for activin receptor-like kinase 1 (ALK1). | Regulation of the ALK1 ligands, BMP9 and BMP10.
Li W, Salmon RM, Jiang H, Morrell NW. | 07/15/2017 |
| Forced expression of BMP10 in gastric cancer (GC) cells inhibited its growth and migration, while knocking down the expression of BMP10 in GC cells promoted cell growth, migration, and metastasis. | BMP10 inhibited the growth and migration of gastric cancer cells.
Lei H, Wang J, Lu P, Si X, Han K, Ruan T, Lu J. | 02/18/2017 |
| The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells. | The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells.
Jiang H, Salmon RM, Upton PD, Wei Z, Lawera A, Davenport AP, Morrell NW, Li W., Free PMC Article | 06/28/2016 |
| BMP10, is elevated in the stenotic colon segment of Hirschsprung disease patients, and BMP10 signaling may play a pivotal role in disease development. | Expression analysis of BMP2, BMP5, BMP10 in human colon tissues from Hirschsprung disease patients.
Wu M, Chen W, Mi J, Chen D, Wang W, Gao H., Free PMC Article | 10/18/2014 |
| Low expression of bone morphogenetic protein-10 is associated with urothelial cancer of the bladder. | Expression of bone morphogenetic protein-10 (BMP10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro.
Zhang N, Ye L, Wu L, Deng X, Yang Y, Jiang WG. | 06/29/2013 |